research Adverse Dermatologic Effects of Cardiovascular Drug Therapy: Part III
Cardiovascular drugs can cause various skin problems, so recognizing these reactions is important.
Search
for
Sort by
Research
690-720 / 1000+ results 
research Central retinal vein occlusion with secondary cilioretinal artery occlusion following oral minoxidil use: A case report and literature review
Oral Minoxidil can cause serious eye problems, but stopping it can improve vision.
research Evaluating the effect of ursodeoxycholic acid (UDCA) in comparison with dexamethasone and diclofenac in a rat model of rheumatoid arthritis
UDCA reduces inflammation and joint damage in rheumatoid arthritis.
research Simultaneous Quantification of Dutasteride and Silodosin Using a Stability-Indicating RP-HPLC Approach
The method accurately and quickly measures silodosin and dutasteride in mixtures.
research EXPERIENCE WITH ANIFROLUMAB IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS WITH NEUROLOGICAL MANIFESTATIONS
Anifrolumab helped some lupus patients reduce steroid use, but safety concerns remain.
research The Relative Efficacy and Safety of Monotherapies for Alopecia Areata: A Network Meta‐Analysis Study
Janus kinase inhibitors are effective and safe for treating Alopecia Areata.
research Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers
Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.
research SYSTEMATIC REVIEW OF ORAL JANUS KINASE INHIBITORS IN ALOPECIA AREATA: INSIGHTS FROM 2020 TO 2025 STUDIES
Oral JAK inhibitors effectively treat alopecia areata and are generally well-tolerated.
research Reporting on Adverse Clinical Events
Certain medications can reduce mortality risk in COPD patients, but others can increase risks of cardiovascular issues, postoperative delirium, and other adverse effects.
research Baricitinib Provides Sustained, Long-Term Efficacy With Consistent Safety for Up to 5 Years of Treatment in Adults With Severe Alopecia Areata: Final Results From BRAVE-AA1 and BRAVE-AA2
Baricitinib is effective and safe for treating severe alopecia areata for up to 5 years.
research Ponatinib-induced pityriasis rubra pilaris-like adnexal dysmaturation: A case report
Ponatinib can cause a rare skin reaction that resolves with topical treatment and temporary drug discontinuation.
research Does Inhibition of Aldose Reductase Contribute to the Anti-Inflammatory Action of Setipiprant?
Setipiprant may reduce inflammation by blocking an enzyme called aldose reductase.
research Update: baricitinib for alopecia areata
Baricitinib is effective and safe for treating severe alopecia areata with ongoing use.
research The Advances of Broad-Spectrum and Hot Anti-Coronavirus Drugs
We need safe, affordable drugs to fight coronaviruses effectively.
research Synthesis of avicequinone c and analogs toward the study of 5α-reductase inhibitory activity
2-Hydroxy-1,4-naphthoquinone is a strong 5α-reductase inhibitor.
research FDA approval of Deuruxolitinib: A New Treatment Option for Severe Alopecia Areata
Deuruxolitinib is FDA-approved for treating severe alopecia areata.
research Balint’s syndrome—missed or mistaken?
The document concludes that early diagnosis of Balint's syndrome is crucial for effective treatment and that understanding drug interactions, like between ritonavir and statins, is important for patient care.
research A microfluidic application for mass production of drug-loaded polymeric microspheres for a long-acting injectable with IVL-DrugFluidic®, a novel microfluidic microsphere manufacturing platform technology
IVL-DrugFluidic® can mass-produce high-quality, long-acting injectable drug microspheres, improving patient compliance and reducing side effects.
research Differential expression of steroid 5α-reductase isozymes and association with disease severity and angiogenic genes predict their biological role in prostate cancer
SRD5A1 is crucial in advanced prostate cancer, and blocking both SRD5A1 and SRD5A2 is more effective than targeting SRD5A2 alone.
research Rebound effect associated with JAK inhibitor use in the treatment of alopecia areata
Stopping JAK inhibitor treatment for hair loss can lead to worse hair loss than before the treatment.
research Use of virtual reality during scalp injections: A randomized interventional crossover study
Virtual reality can reduce pain during scalp injections.
research PROTECTIVE EFFECT OF METHANOL EXTRACT OF RUSSELIA EQUISETIFORMIS AGAINST PARACETAMOL-INDUCED HEPATOTOXICITY IN WISTAR RATS
Russelia equisetiformis extract protects against liver damage from paracetamol.
research Sorafenib-Induced Pityriasis Rubra Pilaris-like Eruption: A Case Report
Sorafenib can cause rare skin reactions, but treatment can continue with additional care.
research finasteride, n.
research Five-Alpha Reductase Inhibitor and Breast Cancer Risk in Men: A Systematic Review
Taking 5-alpha reductase inhibitors does not increase breast cancer risk in men.
research Agitation as a Paradoxical Effect of Divalproex Sodium: A Case Report
Divalproex sodium can sometimes worsen behavior in some patients.
research Experimental and Finite Element Analysis of a Residual Hair Keratin‐based Hydrogel with Calcium for Atorvastatin Sequestration, Release, and In Vitro Activity
Keratin-based hydrogels with calcium are effective for delivering anti-fibrotic drugs.
research Betulinic acid exerts anti‐hepatitis C virus activity via the suppression of NF ‐κB‐ and MAPK ‐ERK 1/2‐mediated COX ‐2 expression
Betulinic acid can help treat hepatitis C by stopping virus replication.
research Platelet-Rich Plasma for Degenerative Spine Disease: A Brief Overview
PRP shows promise for spinal pain but needs more guidelines before widespread use.
research [Retracted] Mechanism of Anti‐Inflammatory Drugs in the Early Treatment of Oral Gingival Mucosa and Soft Tissue Trauma
Levofloxacin and metronidazole reduce inflammation and speed up healing in gingival wounds.